This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2019 Jan;59(1):113-117.

doi: 10.1111/head.13444. Epub 2018 Nov 19.

The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

Peer Tfelt-Hansen¹, Elizabeth Loder²

Affiliations

Affiliations

¹ Danish Headache Center, University Hospital, Rigshospitalet-Glostrup Hospital, Glostrup, Denmark.
² Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 30451300
DOI: 10.1111/head.13444

Review

The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

Peer Tfelt-Hansen et al. Headache. 2019 Jan.

. 2019 Jan;59(1):113-117.

doi: 10.1111/head.13444. Epub 2018 Nov 19.

Authors

Peer Tfelt-Hansen¹, Elizabeth Loder²

Affiliations

¹ Danish Headache Center, University Hospital, Rigshospitalet-Glostrup Hospital, Glostrup, Denmark.
² Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 30451300
DOI: 10.1111/head.13444

No abstract available

Keywords: CGRP antagonists; miregepant; ubrogepant.

PubMed Disclaimer

Comment in

Further Questioning of the Significance of the Gepants.
Nguyen J, Hu D. Nguyen J, et al. Headache. 2019 Nov;59(10):1829-1830. doi: 10.1111/head.13672. Headache. 2019. PMID: 31710109 No abstract available.
Further Questioning of the Significance of the Gepants: A Response.
Loder EW, Tfelt-Hansen P. Loder EW, et al. Headache. 2019 Nov;59(10):1831. doi: 10.1111/head.13683. Headache. 2019. PMID: 31710110 No abstract available.

Similar articles

Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Moreno-Ajona D, et al. Curr Opin Neurol. 2020 Jun;33(3):309-315. doi: 10.1097/WCO.0000000000000806. Curr Opin Neurol. 2020. PMID: 32251023 Review.
Ubrogepant to treat migraine.
Dhir A. Dhir A. Drugs Today (Barc). 2020 Jul;56(7):459-467. doi: 10.1358/dot.2020.56.7.3157311. Drugs Today (Barc). 2020. PMID: 32648856
Ubrogepant for the treatment of migraine.
Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L. Curto M, et al. Expert Opin Pharmacother. 2020 May;21(7):755-759. doi: 10.1080/14656566.2020.1721462. Epub 2020 Feb 3. Expert Opin Pharmacother. 2020. PMID: 32011192 Review.
Ubrogepant: First Approval.
Scott LJ. Scott LJ. Drugs. 2020 Feb;80(3):323-328. doi: 10.1007/s40265-020-01264-5. Drugs. 2020. PMID: 32020557 Free PMC article. Review.
Atogepant for migraine.
Bedrin K, Ailani J. Bedrin K, et al. Drugs Today (Barc). 2022 Aug;58(8):399-405. doi: 10.1358/dot.2022.58.8.3408815. Drugs Today (Barc). 2022. PMID: 35983926

See all similar articles

Cited by

Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine.
Yang L, Xu M, Bhuiyan SA, Li J, Zhao J, Cohrs RJ, Susterich JT, Signorelli S, Green U, Stone JR, Levy D, Lennerz JK, Renthal W. Yang L, et al. Neuron. 2022 Jun 1;110(11):1806-1821.e8. doi: 10.1016/j.neuron.2022.03.003. Epub 2022 Mar 28. Neuron. 2022. PMID: 35349784 Free PMC article.
The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
van Hoogstraten WS, MaassenVanDenBrink A. van Hoogstraten WS, et al. J Headache Pain. 2019 May 16;20(1):54. doi: 10.1186/s10194-019-1007-y. J Headache Pain. 2019. PMID: 31096904 Free PMC article. Review.
Therapeutic novelties in migraine: new drugs, new hope?
Do TP, Guo S, Ashina M. Do TP, et al. J Headache Pain. 2019 Apr 17;20(1):37. doi: 10.1186/s10194-019-0974-3. J Headache Pain. 2019. PMID: 30995909 Free PMC article. Review.
Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.
Haanes KA, Edvinsson L. Haanes KA, et al. CNS Drugs. 2019 Jun;33(6):525-537. doi: 10.1007/s40263-019-00630-6. CNS Drugs. 2019. PMID: 30989485 Review.
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials.
Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, Wang Z. Gao B, et al. Front Pharmacol. 2020 Jan 24;10:1577. doi: 10.3389/fphar.2019.01577. eCollection 2019. Front Pharmacol. 2020. PMID: 32038251 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program